Two drugmakers petitioned the U.S. Supreme Court to reinstate mail-order access to mifepristone, aiming to maintain availability of a key abortion method amid legal challenges, which is crucial for developers and tech professionals in healthcare IT focusing on telemedicine and pharmaceutical distribution logistics. Additionally, UCB acquired Candid Therapeutics for $2 billion upfront, expanding its autoimmune disease therapy portfolio, signaling a trend towards larger companies absorbing smaller biotechs for specialized treatments.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



